中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
6期
750-751
,共2页
癌,小细胞%化疗%复方苦参注射液%卡铂%依托泊苷
癌,小細胞%化療%複方苦參註射液%卡鉑%依託泊苷
암,소세포%화료%복방고삼주사액%잡박%의탁박감
Cancer,small cell%Chemotherapy%Compound kushen injection%Carboplatin%Etoposide
目的 观察复方苦参注射液联合卡铂+依托泊苷(CE方案)治疗小细胞肺癌的近期疗效和毒性反应.方法 将64例小细胞肺癌患者按住院先后顺序分为2组,各32例,研究组给予复方苦参注射液联合CE方案化疗,对照组单纯给予CE方案化疗,治疗2个周期后评价疗效.结果 研究组近期有效率为78.1%(25/32),对照组为71.9%(23/32),2组比较差异无统计学意义(P>0.05).研究组生活质量(卡氏评分)提高率为56.3%(18/32),对照组为34.4%(11/32),2组比较差异有统计学意义(P<0.05).研究组发生Ⅱ度以上白细胞下降者17例,发生率为53.1%;对照组发生Ⅱ度以上白细胞下降者23例,发生率为71.9%,2组比较差异有统计学意义(P<0.05).结论 复方苦参注射液在小细胞肺癌化疗中可以起到减轻不良反应、提高生活质量的作用.
目的 觀察複方苦參註射液聯閤卡鉑+依託泊苷(CE方案)治療小細胞肺癌的近期療效和毒性反應.方法 將64例小細胞肺癌患者按住院先後順序分為2組,各32例,研究組給予複方苦參註射液聯閤CE方案化療,對照組單純給予CE方案化療,治療2箇週期後評價療效.結果 研究組近期有效率為78.1%(25/32),對照組為71.9%(23/32),2組比較差異無統計學意義(P>0.05).研究組生活質量(卡氏評分)提高率為56.3%(18/32),對照組為34.4%(11/32),2組比較差異有統計學意義(P<0.05).研究組髮生Ⅱ度以上白細胞下降者17例,髮生率為53.1%;對照組髮生Ⅱ度以上白細胞下降者23例,髮生率為71.9%,2組比較差異有統計學意義(P<0.05).結論 複方苦參註射液在小細胞肺癌化療中可以起到減輕不良反應、提高生活質量的作用.
목적 관찰복방고삼주사액연합잡박+의탁박감(CE방안)치료소세포폐암적근기료효화독성반응.방법 장64례소세포폐암환자안주원선후순서분위2조,각32례,연구조급여복방고삼주사액연합CE방안화료,대조조단순급여CE방안화료,치료2개주기후평개료효.결과 연구조근기유효솔위78.1%(25/32),대조조위71.9%(23/32),2조비교차이무통계학의의(P>0.05).연구조생활질량(잡씨평분)제고솔위56.3%(18/32),대조조위34.4%(11/32),2조비교차이유통계학의의(P<0.05).연구조발생Ⅱ도이상백세포하강자17례,발생솔위53.1%;대조조발생Ⅱ도이상백세포하강자23례,발생솔위71.9%,2조비교차이유통계학의의(P<0.05).결론 복방고삼주사액재소세포폐암화료중가이기도감경불량반응、제고생활질량적작용.
Objective To observe the recent clinical effects and the side effects of Compound Kushen Injection combined with chemotherapy for small cell lung cancer( SCLC). Methods Totally 64 patients were randomized into two groups. The treatment group received Compound Kushen injection in combination chemotherapy;control group received chemotherapy alone. Results The recent clinical effects of two groups had no significance (78.1% in the trial group vs. 71.9% in the control group) (P >0.05). However, significant differences were noted between the two groups in the improvement rate of quality of life(56.3% in the trial group vs. 34.4% in the control group) ( P < 0.05 ). In the treatment group Ⅱ degrees of leukocytes decrease rate was lower than that in the control group(P <0.05). Conclusion Compound Kushen injection showes good efficacy of attenuation and synergism regarding improving quality of hie in patients with small cell lung cancer.
